Every 8-K that Nutriband Inc. (NTRB) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow NTRB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NTRB filings page.
Nutriband Inc. said its publicly traded warrants (Nasdaq: NTRBW) will expire under their original terms at 5:00 p.m. Eastern Time on September 30, 2026. Trading in the warrants will cease at market close that day, after which they will be removed from Nasdaq listing.
Any warrants still unexercised at expiration will be voided and have no further value. The expiration occurs automatically under the Warrant Agreement and requires no action from holders; Nutriband's common stock is unaffected and will continue to trade on Nasdaq under NTRB.
Nutriband Inc. entered into an amended three-year $5,000,000 credit line facility on June 1, 2026. The revolving line replaces a prior $5,000,000 facility that had been scheduled to expire on July 13, 2026 and carries interest at 7% per annum on drawdowns.
The lender cannot convert amounts outstanding under the credit line into common stock, so this financing remains straight debt rather than potential equity dilution. The company states that the facility is intended to provide funding through the FDA approval process and into commercial-scale manufacturing for its patented lead product, AVERSA™ Fentanyl, an abuse-deterrent fentanyl transdermal system.
Nutriband Inc. filed a current report to share a press release under Regulation FD. The company has selected a commercial worldwide brand name candidate for its lead product, an abuse-deterrent fentanyl transdermal patch built on its AVERSA™ technology, and will submit the name and labeling to the FDA and other regulators for review and approval. The name is also being filed with the U.S. Patent and Trademark Office to secure trademark protection. Nutriband cites a market analysis suggesting its abuse-deterrent fentanyl transdermal system could reach peak annual U.S. sales between $80 million and $200 million, while it continues development for major global markets and highlights AVERSA’s patent coverage across 46 countries.
Nutriband Inc. reported that its Board of Directors approved the immediate termination of the agreement to sell its subsidiary, Pocono Pharmaceuticals, Inc., to Earth Vision Bio Inc. The decision was made on February 13, 2026 after the buyer failed to pay required late fees.
The buyer had not closed by the December 31, 2025 contractual closing date and was obligated to pay late fees under the purchase agreement. Nutriband states it received $30,000 in late fees but has not received any further payments since January 21, 2026, prompting the termination.
Nutriband, Inc. held its 2026 Annual Meeting of Stockholders on January 24, 2026, where shareholders elected seven directors to one-year terms and ratified Sadler, Gibb & Associates, LLC as independent auditor for 2025.
Stockholders also approved an amendment to the Articles of Incorporation increasing authorized preferred stock from 10,000,000 to 20,000,000 shares, and supported the advisory “say on pay” vote for executive compensation. In an advisory vote on frequency, shareholders favored holding the say-on-pay vote every one year.
After the meeting, the Board appointed two new directors, Alessandro Puddu, an Italian Chartered Accountant and Statutory Auditor with extensive audit and corporate advisory experience, and Viorica Carlig, a manager in the aircraft services industry with significant management, growth, and regulatory compliance experience and advanced degrees in economics, business, law, and commerce.
Nutriband Inc. filed a current report on Form 8-K to furnish information under Item 7.01, Regulation FD Disclosure. The company refers readers to an attached press release dated October 28, 2025, filed as Exhibit 99.1.
Nutriband’s common stock (symbol NTRB) and warrants (symbol NTRBW) are listed on The Nasdaq Stock Market LLC. The report is signed on behalf of Nutriband Inc. by Chief Executive Officer Gareth Sheridan.